EUVIMEDEUVIMED entdecken
Crossref

Clinical Validation of Unani Pharmacopoeial Formulation Sharbat-e-Ejaz in Sual-e-Yabis (Dry Cough)

Irfan Ahmed, Nikhat Shaikh, MD Manzar Alam, Arjumand Shah, Mohammed Sheeraz, Nighat Anjum

Acta Pharma Reports · 02.09.2022 · 1 (2) · 1-3

DOI: 10.51470/apr.2022.01.02.01 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Pharma Reports, online erschienen am 25.09.2022. Verfasst von Irfan Ahmed und 5 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Sual-e-Yabis (dry cough) is a common respiratory ailment described in classical Unani texts as a condition primarily of Yabusiyat (dryness) affecting the respiratory tract. Sharbat-e-Ejaz is a compound Unani formulation included in the Unani Pharmacopoeia of India (UPI) with documented anti-tussive and mucolytic properties.

Objective

To clinically validate the efficacy and safety of Sharbat-e-Ejaz in patients with Sual-e-Yabis through a multi-centre open-label clinical trial.

Methods

A total of 128 patients (Male: 88, Female: 40) with confirmed diagnosis of Sual-e-Yabis were enrolled from four CCRUM research institutes. The formulation was administered orally for four weeks with assessments at baseline, 2nd week (1st follow-up) and 4th week (end of treatment). Primary outcome was assessed using the Visual Analogue Scale (VAS). Laboratory investigations including haematological and biochemical parameters were performed to assess safety.

Results

Mean VAS score significantly decreased from 7.91 ± 1.35 at baseline to 2.69 ± 1.18 at end of treatment, reflecting a 65.9% reduction (p < 0.001). No clinically significant adverse changes were observed in laboratory parameters.

Conclusion

Sharbat-e-Ejaz demonstrated significant clinical efficacy and acceptable safety profile in the management of Sual-e-Yabis, supporting its validation as a standard Unani therapeutic formulation.

Zitieren

APA

Ahmed, I., Shaikh, N., Alam, M. M., Shah, A., Sheeraz, M., & Anjum, N. (2022). Clinical Validation of Unani Pharmacopoeial Formulation Sharbat-e-Ejaz in Sual-e-Yabis (Dry Cough). Acta Pharma Reports, 1(2), 1-3. https://doi.org/10.51470/apr.2022.01.02.01

Vancouver

Ahmed I, Shaikh N, Alam MM, Shah A, Sheeraz M, Anjum N. Clinical Validation of Unani Pharmacopoeial Formulation Sharbat-e-Ejaz in Sual-e-Yabis (Dry Cough). Acta Pharma Reports. 2022;1(2):1-3. doi:10.51470/apr.2022.01.02.01

BibTeX
@article{Ahmed2022,
  author = {Ahmed, Irfan and Shaikh, Nikhat and Alam, MD Manzar and Shah, Arjumand and Sheeraz, Mohammed and Anjum, Nighat},
  title = {Clinical Validation of Unani Pharmacopoeial Formulation Sharbat-e-Ejaz in Sual-e-Yabis (Dry Cough)},
  journal = {Acta Pharma Reports},
  year = {2022},
  volume = {1},
  number = {2},
  pages = {1--3},
  doi = {10.51470/apr.2022.01.02.01}
}
Kostenlos starten →